Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach-Reference-Cited by-同舟云学术

Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach

Published:2021-05 Issue: Volume:Volume 15 Page:2193-2210
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Kanwal Ummarah^ORCID,Mukhtar Shahid,Waheed Muzzamil,Mehreen Arifa,Abbas Nasir^ORCID,Shamim Rahat^ORCID,Hussain Khalid^ORCID,Rasool Fatima,Hussain Amjad,Bukhari Nadeem Irfan^ORCID

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference38 articles.

1. Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride

2. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients

3. Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis

4. Interaction between Amlodipine and Simvastatin in Patients with Hypercholesterolemia and Hypertension

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmaceutical product development: a “quality by design” (QbD) approach;Dosage Forms, Formulation Developments and Regulations;2024

2. Chemometrics on pharmaceuticals;Chemometrics;2024

3. A quality by design approach in oral extended release drug delivery systems: where we are and where we are going?;Journal of Pharmaceutical Investigation;2022-11-18

4. Quality by Design (QbD) application for the pharmaceutical development process;Journal of Pharmaceutical Investigation;2022-08-29

5. Development of Optimized Sumatriptan–Prochlorperazine Combined Orodispersible Films Without Disintegrant: in vitro, ex vivo and in vivo Characterization;AAPS PharmSciTech;2022-06-02